Ad-hoc | 16 March 2015 11:12

Cytos Biotechnology AG: Extraordinary Shareholders’ Meeting approves all resolutions

Cytos Biotechnology AG / Key word(s): AGM/EGM

2015-03-16 / 11:12
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

Extraordinary Shareholders’ Meeting of Cytos Biotechnology Ltd. approves all resolutions

Schlieren (Zurich), Switzerland, March 16, 2015 – Cytos Biotechnology Ltd (“Cytos” or the “Company”), announced today that its shareholders have approved all resolutions at today’s Extraordinary Shareholders’ Meeting. These resolutions, among other things, consist of an ordinary capital increase of 77.49 million shares which will be used to exchange the outstanding convertible bonds into shares once the convertible bond restructuring proposal becomes final and binding which is expected to be in the second half of April 2015. After the exchange of the bonds into shares, a total of around 108 million Cytos shares with a nominal value of CHF 0.03 each will be issued and outstanding.

The Extraordinary Shareholders’ Meeting of Cytos Biotechnology Ltd took place at the Company’s headquarters in Schlieren (Zurich), Switzerland. It was attended by 52 shareholders. 4’757’980 shares or 15.6% of a total of 30,525,276 shares were represented.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com

End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=EHEMAXUOQL
Document title: Cytos_EGM_150316

2015-03-16 News transmitted by EQS Schweiz AG. www.eqs.com – news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

Language:	English
Company:	Cytos Biotechnology AG
	Wagistr. 25
	8952 Schlieren
	Switzerland
Phone:	+41 44 733 4747
Fax:	+41 44 733 4740
E-mail:	info@cytos.com
Internet:	www.cytos.com
ISIN:	CH0011025217, CH0029060735
Valor:	–
Listed:	Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; SIX

End of News EQS Group News-Service

333433  2015-03-16